Ucb Inc Company Profile

✉ Email this page to a colleague

UCB INC has forty-two approved drugs.

There are thirty-six US patents protecting UCB INC drugs.

There are four hundred and ninety-three patent family members on UCB INC drugs in fifty-two countries and forty-five supplementary protection certificates in fifteen countries.

International Patents:	493
US Patents:	36
Tradenames:	29
Ingredients:	24
NDAs:	42
Drug Master File Entries:	1
Patent Litigation for Ucb Inc:	See patent lawsuits for Ucb Inc

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	ALBUTEROL SULFATE	albuterol sulfate	TABLET;ORAL	073120-001	Sep 29, 1992		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Ucb Inc	UNIRETIC	hydrochlorothiazide; moexipril hydrochloride	TABLET;ORAL	020729-001	Jun 27, 1997		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Ucb Inc	GASTROCROM	cromolyn sodium	CAPSULE;ORAL	019188-001	Dec 22, 1989		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	VIMPAT	lacosamide	SOLUTION;ORAL	022255-001	Apr 20, 2010	RE38551	⤷ Subscribe
Ucb Inc	NEUPRO	rotigotine	FILM, EXTENDED RELEASE;TRANSDERMAL	021829-002	May 9, 2007	6,884,434	⤷ Subscribe
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-005	May 12, 2016	6,784,197	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	1000 mg	➤ Subscribe	2007-01-24
➤ Subscribe	Tablets	50 mg, 100 mg, 150 mg, and 200 mg	➤ Subscribe	2012-10-29
➤ Subscribe	Extended-release Tablets	1000 mg	➤ Subscribe	2011-01-07
➤ Subscribe	Tablets	7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg	➤ Subscribe	2004-01-15
➤ Subscribe	Extended-release Transdermal Film	1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr	➤ Subscribe	2013-11-26
➤ Subscribe	Oral Solution	10 mg/mL	➤ Subscribe	2012-10-29
➤ Subscribe	Injection	10 mg/mL, 20 mL	➤ Subscribe	2016-06-30
➤ Subscribe	Orally Disintegrating Tablets	0.25 mg, 0.5 mg, 1 mg and 2 mg	➤ Subscribe	2005-12-27

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1110543	SPC/GB08/005	United Kingdom	⤷ Subscribe	SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
1033978	CA 2006 00020	Denmark	⤷ Subscribe	PRODUCT NAME: ROTIGOTINE
1110543	08C0004	France	⤷ Subscribe	PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.